Europe Next Generation Cancer Diagnostics Market Size & Outlook
Europe next generation cancer diagnostics market, 2018-2030 (US$M)
Related Markets
Europe next generation cancer diagnostics market highlights
- The Europe next generation cancer diagnostics market generated a revenue of USD 4,539.4 million in 2023.
- The market is expected to grow at a CAGR of 8.7% from 2024 to 2030.
- In terms of segment, next generation sequencing was the largest revenue generating technology in 2023.
- Next Generation Sequencing is the most lucrative technology segment registering the fastest growth during the forecast period.
- Country-wise, Germany is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 4,539.4 million |
| Market revenue in 2030 | USD 8,150.6 million |
| Growth rate | 8.7% (CAGR from 2023 to 2030) |
| Largest segment | Next generation sequencing |
| Fastest growing segment | Next Generation Sequencing |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Next Generation Sequencing, QPCR & Multiplexing, LOAC & RT-PCR, Protein Microarrays, DNA Microarrays |
| Key market players worldwide | Johnson & Johnson, Illumina Inc, Novartis AG ADR, Roche, Koninklijke Philips NV, Qiagen NV, Agilent Technologies Inc, Abbott Laboratories, Thermo Fisher Scientific Inc, GE HealthCare Technologies Inc Common Stock |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.9% of the global next generation cancer diagnostics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 6,491.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Next Generation Cancer Diagnostics Market Scope
Next Generation Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe next generation cancer diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to next generation cancer diagnostics market will help companies and investors design strategic landscapes.
Next generation sequencing was the largest segment with a revenue share of 36.88% in 2023. Horizon Databook has segmented the Europe next generation cancer diagnostics market based on next generation sequencing, qpcr & multiplexing, loac & rt-pcr, protein microarrays, dna microarrays covering the revenue growth of each sub-segment from 2018 to 2030.
Presence of the leading players such as Roche Holding AG, GE Healthcare, Phillips, Novartis, Qiagen NV, and Almac Group Limited are the major contributors for the second largest share of the European market in next generation cancer diagnostics market.
Moreover, active participation of the European Molecular Biology Laboratory (EMBL) in projects for development of novel approaches for early diagnosis, detection, and prevention as well as for molecular pathogenesis of colorectal cancer is supportive for the estimated revenue in 2014.
Reasons to subscribe to Europe next generation cancer diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe next generation cancer diagnostics market databook
-
Our clientele includes a mix of next generation cancer diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe next generation cancer diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe next generation cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe next generation cancer diagnostics market size, by country, 2018-2030 (US$M)
Europe Next Generation Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
